FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES

摘要

The invention relates to fatty acid antiviral conjugates; compositions comprising an effective amount of a fatty acid antiviral conjugate; and methods for treating or preventing a viral infection comprising the administration of an effective amount of a fatty acid antiviral conjugate.

主权项

1. A molecular conjugate comprising an antiviral agent and a fatty acid directly or indirectly covalently linked, selected from omega-3 fatty acids, fatty acids metabolized in vivo into omega-3 fatty acids, or lipoic acid, with the proviso that the molecular conjugate is not (4Z,7Z,10Z,13Z,16Z,19Z)—N-(1-((2S,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)docosa-4,7,10,13,16,19-hexaenamide, (5Z,8Z,11Z,14Z,17Z)—N-(1-((2S,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)icosa-5,8,11,14,17-pentaenamide, (9Z,12Z,15Z)—N-(1-((2S,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)octadeca-9,12,15-trienamide, (4Z,7Z,10Z,13Z,16Z,19Z)-((2S,5S)-5-(4-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl docosa-4,7,10,13,16,19-hexaenoate, (5Z,8Z,11Z,14Z,17Z)-((2S,5S)-5-(4-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenamido)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl icosa-5,8,11,14,17-pentaenoate, (9Z,12Z,15Z)-((2S,5S)-5-(4-((9Z,12Z,15Z)-octadeca-9,12,15-trienamido)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl octadeca-9,12,15-trienoate, (4Z,7Z,10Z,13Z,16Z,19Z)-((2S,5S)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl docosa-4,7,10,13,16,19-hexaenoate, (7Z,10Z,13Z,16Z,19Z)—N-(1-((2S,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)docosa-7,10,13,16,19-pentaenamide, (7Z,10Z,13Z,16Z,19Z)-((2S,5S)-5-(4-((7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenamido)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl docosa-7,10,13,16,19-pentaenoate, (7Z,10Z,13Z,16Z,19Z)-((2S,5S)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl docosa-7,10,13,16,19-pentaenoate, (5Z,8Z,11Z,14Z,17Z)-((2S,5S)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl icosa-5,8,11,14,17-pentaenoate, (9Z,12Z,15Z)-((2S,5S)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl octadeca-9,12,15-trienoate, or (4Z,7Z,10Z,13Z,16Z,19Z)-((2S,3S,5S)-3-azido-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl docosa-4,7,10,13,16,19-hexaenoate;